Navigation Links
BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Date:1/12/2009

IV iron and Nephrologists report preferring a preventative strategy employing maintenance dosing to manage iron deficiency versus the reactive strategy in line with repletion dosing that is most common in CKD. Despite these differences, Nephrologists report optimistic projections for Feraheme in both the dialysis and CKD markets, drawing share from American Regent's/Fresenius Medical Care's Venofer and Watson's Ferrlecit.

Many potential new products are also on the horizon in the phosphate binder market, albeit longer term. New products will likely be welcome additions as Nephrologists report that over one-third of their patients are not well-controlled on currently available binders. A binder that could be given with less frequency (as opposed to every meal) would likely have a considerable impact on market dynamics as the largest group of Nephrologists report patient non-compliance due to the frequency with which current binders have to be taken as the main reason phosphorus is difficult to control in dialysis patients. A more near-term shift in market dynamics will likely come from the recent introduction of generic calcium acetate from Roxane Laboratories, as very few Nephrologists oppose the substitution of a generic for Fresenius Medical Care's PhosLo. Another recent market shift came with the introduction of Genzyme's Renvela in Q108. Although the growth of Renvela seems to be fueled by cannibalization of Renagel, Nephrologists expect increases in overall sevelamer share in both dialysis and CKD, as well as increases in Shire's Fosrenol, while continued shifts are expected away from calcium based binders.

The proposed bundling structure is also expected to greatly impact the Vitamin D market, with over 50% of Nephrologists reporting they would shift away from IV Vitamin D to oral Vitamin D as their first line choice in hemodialysis patients. Another change in this market may be in the use of Nutritional Vitamin D, with
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
2. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
3. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
4. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
5. BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
6. New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists
7. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
8. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
9. CEL-SCI Corporation Releases Letter to Shareholders
10. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
11. The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. ... (eslicarbazepine acetate) for use as a once-daily adjunctive ... with epilepsy who are not satisfactorily controlled with conventional ... in patients under 18 years of age. ... disorders and according to Epilepsy Canada, it affects 0.6% ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of ... to announce the relaunch of his highly informative blog, now ... called “ What are Stem Cells ?” Dr. Harman’s ... foundation in the basics of stem cell therapy so that ... type of treatment when considering regenerative medicine. , A veterinarian ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... COTTAGE, N.Y., Jan. 28 XTL Biopharmaceuticals Ltd. (Nasdaq: ... its December 8, 2008 press release regarding the Company,s activities ... company to merge into or with XTL. The Company is ... it by both US and foreign-based companies who operate in ...
... as VP of Business Development , ... Olyphant, PA (PRWEB) January 28, ... company, announced today the hiring of Mr. Terry Ladd as Vice President ... 1994-2003 as Executive Director, Business Development and Marketing., , , , ,Mr. ...
... PALO ALTO, Calif., Jan. 28 In light of an ... (Nasdaq: CVTX ) confirmed that it had received ... an unsolicited proposal by Astellas to acquire CV Therapeutics at ... Astellas board approval and other conditions. After careful deliberation, ...
Cached Biology Technology:XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives 2Calvert Labs Announces the Hiring of Terry Ladd 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... a huge portion of real estate in western North ... and fossils very different from those in adjacent terranes. ... tectonic styles, metamorphism, and volcanic origins, much like the ... new Geological Society of America Special Paper brings together ...
... Washington, DCMay 28, 2008The 2008 American Society for ... Diagnostic Immunology is presented to Steven A. Rosenberg, ... Surgery, Uniformed Services University of the Health Sciences, ... of Medicine and Health Sciences. Sponsored by Abbott ...
... for Microbiology (ASM) Merck Irving S. Sigal Memorial Award ... Genetics and Microbiology, University of Texas at Austin. Sponsored ... Memorial Award is presented in memory of Irving S. ... therapies to treat HIV/AIDS, to recognize excellence in basic ...
Cached Biology News:American Society for Microbiology honors Steven A. Rosenberg 2
... introduced the highly potent TURBO DNase (patent pending) ... was set in DNA removal capabilities. TURBO DNase ... that is much more efficient than wild type ... unwanted DNA. TURBO DNase binds DNA substrates 6-fold ...
... IEC Centra CL3 series is designed ... research and clinical applications at a ... package includes quick connect rotors and ... yet intuitive interface allows you to ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... DNA Polymerase I Large (Klenow) Fragment, Exonuclease ... lacks both the 5´→3´ and the 3´→5´ ... DNA Polymerase I (1,2). It is used ... strand displacement amplification (5). Klenow Fragment, Exonuclease ...
Biology Products: